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Abstract
Background: Antidepressant-worsening suicidal ideation is a rare but serious phenomenon. This study aimed to test for 
association between antidepressant-worsening suicidal ideation and polymorphisms of BDNF/NTRK2 neurotrophin pathway 
genes, known to be involved in depression and suicide.
Methods: This was a case-control study comparing patients with antidepressant-worsening suicidal ideation to patients 
without. Patients were collected from the GENESE cohort (3771 depressed tianeptine-treated outpatients). Antidepressant-
worsening suicidal ideation was defined by an increase of at least 2 points on the Montgomery-Åsberg Depression Rating 
Scale-item10 during treatment. Controls were matched for age, sex, and baseline Montgomery-Åsberg Depression Rating 
Scale-item10 score. Thirteen single nucleotide polymorphisms covering 5 BDNF/NTRK2 pathway genes were genotyped.
Results: A total 78 cases and 312 controls were included. Two NTRK2 single nucleotide polymorphisms were associated to 
antidepressant-worsening suicidal ideation: rs1439050 (P = .01) and rs1867283 (P = .04). Association with rs1439050 remained 
significant after adjustment for potentially confounding factors, including previous suicide attempts (P < .01).
Conclusions: This naturalistic prospective study is consistent with previous studies on highlighting the potential role of the 
neurotrophin pathway, and especially of NTRK2, in antidepressant-worsening suicidal ideation.
Keywords: suicide, depression, antidepressant drugs, pharmacogenetics, neutrotrophin
Introduction
Increase of suicidal thoughts during antidepressant treatment is 
a rare but serious phenomenon that has been reported for vari-
ous antidepressant drugs such as selective serotonin reuptake 
inhibitors (Zisook et al., 2009) but also tricyclic antidepressants 
(Perroud et  al., 2009), serotonin and norepinephrine reuptake 
inhibitors (Baek et al., 2015), or various antidepressants (Courtet 
et  al., 2014), and which has led the FDA to issue a black box 
warning in 2006. Genetic studies, as adoption (Petersen et  al., 
2013) or twin studies (Voracek and Loibl, 2007), have shown 
the role of genetics in suicidal behavior, independently from 
the environment and from mood disorders (Brent and Mann, 
2006). Among the different pathways involved in depression 
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and suicidal behavior, the neurotrophin pathway, also known 
as BDNF/NTRK2 pathway, is a major one to consider. Indeed, in 
depression, both neurotrophic factor BDNF and its high-affinity 
receptor TrkB have been shown to be decreased, at both the RNA 
and protein level (Tripp et  al., 2012). This decrease is revers-
ible with antidepressant treatment (Huang et al., 2008). Siuciak 
et al. (1997) even showed an antidepressant-like effect of a brain 
BDNF-infusion in rodents. Molecular mechanisms of suicide 
also involve the BDNF-NTRK2 pathway. A decrease of BDNF and 
NTRK2 transcription levels (Dwivedi et al., 2009), as well as qual-
itative impairments such as decrease of autophosphorylation 
capacity of TrkB, have been found in postmortem suicide brains 
(Pandey et al., 2008).
Recent pharmacogenetic studies suggest that antidepres-
sant-worsening suicidal ideation (AWSI) could be genetically 
driven (Laje et al., 2007; Brent et al., 2010). Some of these stud-
ies involved genes of the neurotrophin pathway, such as BDNF, 
NTRK2, or transcription factor CREB. Even if AWSI was initially 
described in adolescents and young adults under 25 years, this 
phenomenon could also occur in adults above 25 years, as few 
studies specifically investigated the risk of AWSI in adult pop-
ulations. Apart from the large STAR*D (Perlis RH et al., 2007) 
and GENDEP (Perroud et al., 2009a) consortia, reporting up to 
20% patients experiencing AWSI, the limited number of large 
prospective studies probably reduced the chances to replicate 
or invalidate such results in older subjects. Therefore, in a 
large naturalistic cohort of depressed outpatients treated by 
tianeptine, we tested the association between common vari-
ants of genes of the neurotrophin pathway and the occurrence 
of AWSI.
Methods
Sample
GENESE is a large, prospective, naturalistic cohort of 3771 French 
outpatients diagnosed with major depression and treated with 
tianeptine, one of the most prescribed antidepressants among 
French general practitioners (GPs) (Hérique and Kahn, 2009). 
Dosage of tianeptine was managed by a GP and had to range 
between 12.5 and 37.5 mg/d, according to prescription recom-
mendations. During the first visit, GPs validated the diagnosis of 
major depressive episode (MDE) by checking each DSM-IV crite-
ria for MDE and checked the other inclusion criteria (age above 
18 years and Caucasian ethnicity) and the absence of DSM-IV 
alcohol dependence. They rated suicidal thoughts using a single 
item (item 10, “suicidal thoughts”) of the Montgomery-Åsberg 
Depression Rating Scale (MADRS). Patients self-evaluated 
depressive symptoms at baseline using the Hospital Anxiety 
and Depression Scale, then filled in item 10 of the MADRS at day 
14. Hospital Anxiety and Depression Scale and MADRS item 10 
were finally rated by GPs during the last visit (between day 42 
and day 56)  to assess the evolution of the MDE. DNA was col-
lected at baseline by buccal swab.
AWSI was defined as an increase of at least 2 points on the 
MADRS-item10 between baseline and day 14 or final visit. The 
other inclusion criteria were age above 18 years and Caucasian 
ethnicity. We did not distinguish treatment “emergent” sui-
cidal ideation from treatment “worsening” suicidal ideation, as 
Perroud et al. (2009b) showed that both notions were not refer-
ring to distinct phenotypes. We selected controls matched for 
age, sex, and severity of suicidal thoughts on MADRS-item 10 at 
baseline. A ratio of 4 controls for 1 case was chosen to increase 
statistical power.
Single Nucleotide Polymorphisms (SNP) Selection
SNPs selection was made according to 4 criteria: (1) SNPs of 
neurotrophin pathway genes that had been previously reported 
as associated with either suicide or AWSI, (2) minor allele fre-
quency >5%, (3) distance between 2 SNPs >10 000 bp to limit link-
age disequilibrium, and (4) total number of SNPs <20 because 
of the moderate size of our sample of cases. The priority was 
given to NTRK2 while choosing SNPs, considering its major 
role in antidepressant molecular mechanism of action. A total 
of 13 SNPs was therefore included: rs6265 and rs962369 from 
BDNF; rs10868235, rs1114800, rs1867283, rs1147198, rs1187286, 
rs1439050, and rs1387923 from NTRK2; rs2072446 from p75NTR 
(BDNF and NGF low affinity receptor); rs2551919 and rs4675690 
from CREB (transcription factor downstream from BDNF); and 
rs1360550 from PKC (involved in NTRK2 PLCγ signal cascade).
Genotyping
Genotyping was performed using a 5’ exonuclease assay 
(Taqman, Life Technologies). Assay products were run on an 
Applied Biosystem 7900HT Fast Real-Time PCR System (Life 
Technologies).
Statistics
The case-control single-SNP analysis was performed using a 
logistic regression model as implemented in PLINK (Purcell 
et  al., 2007) (http://pngu.mgh.harvard.edu/~purcell/plink/). 
Empirical P values were estimated by permutation to lower the 
risk of chance finding due to multiple comparisons. Haplotypes 
analysis was also conducted using PLINK. The only results taken 
into account were the results of the omnibus test, which tests all 
observed haplotypes. Clinical data analyses used Student t test 
and chi-square test, and potentially confounding factors were 
controlled for by a logistic regression analysis.
Ethics Statement
The study was performed according to French regulatory guide-
lines and current codes of Good Clinical Practice. Each patient 
was informed about the aims and procedures of the study and 
provided written, signed consent. The study protocol was sub-
mitted to and approved by local independent ethics committees 
(C.P.P., reference no. 08042.)
Results
Clinical Features
Seventy-eight patients met the criteria for the AWSI group and 
312 patients were selected as controls, for a ratio of 4 controls/
case. Mean age at inclusion was 48.2 years, and the sex ratio was 
2 women for 1 man. Table 1 presents the socio-demographic and 
clinical features for both groups. Concerning current episode, 
alcohol abuse, and benzodiazepine coprescription were more 
often reported in cases than controls (5.3% vs 1.0%, respectively; 
P = .03 and 62.2% vs 40.8%, P < .01). Concerning mood disorder, 
the current episode was less frequently a first episode in cases 
(40.3% vs 57.4%, P < .01). Comparing the presence of all DSM-IV 
criteria of major depressive disorder, one item was more fre-
quently rated for cases at baseline, namely agitation (85.3% vs 
75.5%, P = .07), but the difference was not statistically significant. 
Lastly, a history of suicide attempt was much more frequent in 
cases than controls (26.0 vs 6.3, P < .01).
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Single SNP Association Analysis
Two SNPs were significantly associated with AWSI, both being 
located in the NTRK2 gene (Table 2): rs1439050 (P = .01, 1/OR= 1.69) 
and rs1867283 (P = .04, 1/OR= 1.46). Only rs1439050 remained sig-
nificant after the permutation process (P = .02). Given that only 
one SNP among all SNPs tested was a functional one, BDNF SNP 
rs6265, also known as Val66Met and involved in impaired pro-
cessing of proBDNF and secretion of the processed peptide, we 
conducted a genotypic analysis for this particular SNP, which 
did not show any difference between Met/+ carriers and Val/Val 
homozygotes patients (P = .43, 1/OR = 1.36).
Adjustment for Potential Confounding Variables
Given the significant differences of some potentially contami-
nant clinical features between cases and controls, we conducted 
a covariate analysis. After adjustment for past suicide attempts, 
being in a first vs later depressive episode, presence of alcohol 
abuse, or benzodiazepine coprescription, rs1439050 was the 
only SNP remaining significant (P < .01, P = .02, P = .02, and P = .04, 
respectively). On the other hand, after adjustment on the “agita-
tion” item at baseline, rs1439050 and rs1867283 remained asso-
ciated to AWSI (P = .01 and P = .04, respectively).
Subpopulation Analysis
Assessing the role of the rs1439050 G allele in different subpopula-
tions (emergent vs worsening suicidal ideations, with vs without 
suicide attempts history, and younger vs older than 25 years old), 
we found that the association with rs1439050 was maintained 
for (1) patients experiencing worsening suicidal ideation during 
treatment, (2) patients older than 25 years, and (3) patients with-
out a suicide attempt history (P = .02, OR = 1.72; P = .01, OR = 1.72; 
P = .01, OR  =  1.72, all P values resisting permutation processes, 
respectively). Patients with emergent suicidal ideas, younger than 
25 years, or with a suicide attempt history (with a respective num-
ber of cases of 22, 5, and 9) did not reach statistical significance 
(P = .18, OR = .62; P = .67, OR = .75; and P = .45, OR = .67, respectively).
Haplotype Analysis
Three haplotypes, all composed of NTRK2 markers, 
were associated with AWSI: only one involves rs1439050 
(rs1439050|r1187286), with an omnibus test P = .03) lower than 
rs1439050 alone, in accordance with the partial linkage disequi-
librium between these 2 SNPs. The other 2 haplotypes consisted 
of 2 or 3 NTRK2 SNPs (rs10868235|rs11140800, omnibus test P 
= .04, and rs1867283|rs10868235|rs1114080, omnibus test P = .02).
Discussion
In this study, we replicate the findings of Perroud et al. (2009a) 
about NTRK2 SNP rs1439050, as this particular polymorphism 
was associated with an increase of suicidal thoughts during the 
first weeks following the introduction of an antidepressant treat-
ment in the present study. The associations in these 2 studies 
surprisingly go in a different direction (OR = 0.587 in our study, 
OR = 1.268 in the Perroud et al. study (2009b)), although both 
GENDEP and GENESE cohorts consist of Caucasian European 
patients and therefore have the same ethnicity basis. A poten-
tial explanation is that rs1439050, an intronic SNP with no spe-
cific reported role, is not a vulnerability factor per se (i.e., directly 
explaining the phenotype) but rather is in linkage disequilib-
rium with a nearby unidentified functional mutation of NTRK2, 
tagged by the same marker, although with a different allele. The 
nearest SNPs known to induce translation errors (missenses) are 
rs748182988 and rs201875843, with respective positions on chro-
mosome 9 84670950 and 84670940, while the rs1439050 position 
on chromosome 9 is 84673278.
Table 1. Clinical Features of Both Groups
AWSI Group Control Group P value
n = 78 n = 312
Demographic characteristics
Mean (SD)
 Current age (y) 50.0 (14.7) 47.7 (14.2) .23
n (%)
 Men 26 (33.3) 101 (32.4) .87
Current episode characteristics
Mean (SD)
 Total baseline HAD score 26.3 (7.2) 24,9 (6.2) .16
 Baseline depression HAD score 12.6 (4.4) 12.0 (3.9) .30
 Baseline anxiety HAD score 13.7 (4.2) 12.9 (3.5) .14
 Tianeptine dose (mg/d) 36.25 (7.1) 35(7.1) .54
n (%)
 Benzodiazepines coprescription 46 (62.2) 125 (40,8) <.01 *
 Alcohol abuse 4 (5.3) 3 (1.0) .03 *
Mood disorder characteristics
Mean (SD)
 Age at first episode 38.6 (14.9) 34.5 (14.2) .16
 Total number of episodes 3.1 (3.6) 2.4 (1.6) .17
 Cumulative duration of episodes (mo) 41.2 (34.3) 32.9 (26.3) .18
n (%)
 First episodes 31 (40.3) 178 (57.4) <.01 *
 Suicide attempts history 20 (26.0) 17 (5.6) <.01 *
*P value < .05.
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Interestingly, NTRK2 seems to be involved in AWSI regard-
less of the class of antidepressant, as the association has been 
reported for a serotonin reuptake inhibitor (escitalopram), a tri-
cyclic antidepressant (nortriptyline) in the study of Perroud et al. 
(2009a), and now tianeptine, an atypical antidepressant whose 
chemical structure is close to tricyclics. The actual molecular 
mechanism of action of antidepressants on the neurotrophin 
pathway remains unclear, but some studies have recently sug-
gested that TrkB could play a major role, independently of BDNF 
binding. Rantamäki et al. (2011) showed that administration of 
antidepressants to rodents induced an increase of the phospho-
rylation level of TrkB, while BDNF transcription levels remained 
unchanged. This phenomenon was even found to occur in BDNF 
knockout mice, confirming that BDNF binding is not necessary 
for short-term TrkB activation by antidepressants. Even if the 
actual mechanism of autophosphorylation of TrkB by antide-
pressants remains unsolved, as no binding of antidepressants 
on TrkB has ever been found, this activation was interestingly 
replicated for several classes of antidepressants (Rantamäki 
et  al., 2007). A  functional alteration of TrkB could then affect 
the action of antidepressants on the neurotrophin pathway and 
participate in the emergence of side effects such as AWSI.
Interestingly, although having a suicide attempt history is known 
to be a major risk-factor for suicide and AWSI (Courtet et al., 2014), 
association between rs1439050 and AWSI resisted adjustment for 
this confounding variable. Adjustment for alcohol abuse or benzo-
diazepine prescription, both higher in cases, did not alter this asso-
ciation either. The analyses on different subpopulations showed 
that the association with rs1439050 was maintained for patients 
(1) having experienced worsening suicidal ideation, (2) older than 
25 years old, and (3) without suicide attempts history, but did not 
reach statistical significance for patients (1) with emergent suicidal 
ideation, (2) younger than 25 years, and (3) with a suicide attempt 
history. However, the small number of cases in each of these latter 
subgroups (22, 5, and 9 patients, respectively) might partly explain 
this result because of a lack of statistical power. Overall, our clini-
cal features did not determine a clear profile of patients experi-
encing AWSI. While the trend toward a higher rate of agitation 
at diagnosis among cases could support the hypothesis of mixed 
states, mistaken for MDEs and wrongly treated by antidepressants 
(Akiskal et al., 2005), the lower rate of first episodes in cases as well 
as the trend toward a higher number of depressive episodes in 
their history and a longer cumulative duration of depressive epi-
sodes contradict this argument and defend the hypothesis of severe 
multi-treated patients, who might have developed lower sensitivity 
to antidepressants. Besides, this last hypothesis is reinforced by the 
fact that adjustment on the “agitation” item does not alter the sta-
tistical association between AWSI and the rs1439050 SNP. The wors-
ening of suicidal thoughts could then be explained by the lack of 
efficacy of antidepressant drugs on an evolving depressive episode, 
as supposed by Courtet et al. (2014).
There are several limitations to this study. The main one is 
the modest size of our cases sample, despite the very large cohort 
sample from which they were selected, due to the rarity of this 
phenomenon. However, the prospective and naturalistic design 
of this study, and therefore the good reliability and representa-
tiveness of the data, partly balance this lack of statistical power.
Second, our AWSI prevalence (1.8% of the cohort) is lower than 
those reported in the literature (4–20%) (Perroud et al., 2009b). One 
explanation is that GENESE is an outpatient cohort, which excludes 
the most severe depressions, perhaps more exposed to AWSI. 
Another explanation could be a lack of detection of this phenom-
enon: indeed, rating of suicidal thoughts was performed by GPs at 
baseline and final visit or by patients themselves at day 14. Both 
are less accustomed to MADRS rating than specialists, which could 
have induced a detection bias. Nevertheless, studies have shown 
Table 2. Single SNP Analysis of 13 SNPs (Allelic Analysis)
Chromosome Gene SNP Position (bp) Allele AWSI n (%) Controls n (%) P value P value after Permutation 1/OR
2 CREB rs2551919 208430383 C 128 (82.0) 518 (83.0) 0.921 0.98
T 26 (17.3) 106 (17.0)
rs4675690 208507807 C 87(55.5) 334(53.6) 0.676 1.08
T 69 (44.5) 290 (46.4)
9 NTRK2 rs1147198 87275598 A 120 (76.7) 466 (74.7) 0.627 1.11
C 36 (23.3) 158 (25.3)
rs1439050 87288193 G 116 (74.67) 397 (63.6) 0.010* 0.017* 1.69
T 40 (25.3) 227 (36.4)
rs1187286 87415028 A 125 (80.0) 461 (74.0) 0.124 1.41
C 31(20.0) 163 (26.1)
rs1867283 87450766 A 62 (40.0) 308 (49.4) 0.040* 0.072 1.46
G 94 (60.0) 316 (50.7)
rs10868235 87493755 C 62 (40.0) 294 (47.1) 0,119 1.33
T 94 (60.0) 330 (52.9)
rs11140800 87508137 A 94 (60.0) 380 (60.9) 0.844 0.96
C 62 (40.0) 244 (39.1)
rs1387923 87640886 C 70 (44.7) 271 (43.4) 0.773 0.95
T 86 (55.3) 353 (56.6)
11 BDNF rs6265 27679916 A 32 (20.7) 151 (24.2) 0.361 1.23
G 124 (79.3) 473 (75.8)
rs962369 27734420 A 114 (73.3) 493 (79.1) 0.129 0.73
G 42 (26.7) 131 (20.9)
10 PKCε rs1360550 30487760 C 64 (40.8) 250 (40.1) 0.876 0.97
T 92 (59.2) 374 (59.9)
17 p75NTR rs2072446 49510457 C 146 (93.3) 583 (93.4) 0.961 0.98
T 10 (6.7) 41 (6.6)
*P value < .05.
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that a single item rating was as valid approach to assess suicidal 
thoughts (Desseilles et al., 2012) and that self-assessment could be 
as accurate as hetero-evaluation (Moroge et  al., 2014). Moreover, 
MADRS scale was first intended to be assessed by trained as well as 
less-trained caregivers (Davidson et al., 1986). Nevertheless, intra-
rater reliability might be more important in the present study, as 
the definition of the AWSI phenotype is based on a rating differ-
ence between two different time points.
Third, no consensus exists about the definition of AWSI. In 
this study, we chose to favor specificity in the definition of the 
AWSI phenotype at the risk of reducing sensitivity. A larger defi-
nition of AWSI would have raised our prevalence of AWSI: taking 
an increase of at least 1 point instead of 2 on MADRS-item10 as 
AWSI definition would have risen our prevalence to 4.0%, which 
is more consistent with the literature but which also potentially 
implies decreased specificity.
In conclusion, this study reports an association between 
AWSI and SNP rs1439050 of NTRK2 in depressed subjects treated 
by tianeptine. Our findings support the hypothesis of a major 
role of TrkB in antidepressant drugs mechanism of action and 
therefore in AWSI, independently of its activation by BDNF bind-
ing, and whatever the class of antidepressant considered.
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